Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial

The Lancet

Volumn 387, Issue 10013, 2016, Pages 40-52

  Thaçi, Diamant ^a   Simpson, Eric L ^b   Beck, Lisa A ^c   Bieber, Thomas ^d   Blauvelt, Andrew ^e   Papp, Kim ^f   Soong, Weily ^g   Worm, Margitta ^h   Szepietowski, Jacek C ⁱ   Sofen, Howard ^j   Kawashima, Makoto ^k   Wu, Richard ^l   Weinstein, Steven P ^l   Graham, Neil M H ^l   Pirozzi, Gianluca ^m   Teper, Ariel ^m   Sutherland, E Rand ⁿ   Mastey, Vera ^l   Stahl, Neil ^l   Yancopoulos, George D ^l   Ardeleanu, Marius ^l   more..

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF BONN   (Germany)

^e OREGON MEDICAL RESEARCH CENTER   (United States)

^f K Papp Clinical Research and Probity Medical Research   (Canada)

^g Alabama Allergy and Asthma Center   (United States)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ WROCLAW MEDICAL UNIVERSITY   (Poland)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^l REGENERON PHARMACEUTICALS INC   (United States)

^m SANOFI   (France)

ⁿ SANOFI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DUPILUMAB; IL4R PROTEIN, HUMAN; INTERLEUKIN 4 RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BACKACHE; BACTERIAL INFECTION; BODY SURFACE; CELLULITIS; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DERMATITIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ECZEMA AREA AND SEVERITY INDEX; FEMALE; HEADACHE; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; INJECTION SITE REACTION; INVESTIGATOR GLOBAL ASSESSMENT; KAPOSI VARICELLIFORM ERUPTION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NUMERIC RATING SCALE; OUTCOME ASSESSMENT; PERITONSILLAR ABSCESS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SKIN DISEASE ASSESSMENT; SOFT TISSUE INFECTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; CANADA; CLINICAL TRIAL; CZECH REPUBLIC; DERMATITIS, ATOPIC; GERMANY; HUNGARY; JAPAN; MIDDLE AGED; POLAND; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CANADA; CZECH REPUBLIC; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; HUNGARY; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; JAPAN; MALE; MIDDLE AGED; POLAND; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84954271885     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00388-8     Document Type: Article

References (32)

1. LF Eichenfield, WL Tom, SL Chamlin et al. Guidelines of care for the management of atopic dermatitis. Section 1. Diagnosis and assessment of atopic dermatitis J Am Acad Dermatol 70 2014 338 351
2. J Ring, A Alomar, T Bieber et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part 1 J Eur Acad Dermatol Venereol 26 2012 1045 1060
3. LF Eichenfield, WL Tom, TG Berger et al. Guidelines of care for the management of atopic dermatitis. Section 2. Management and treatment of atopic dermatitis with topical therapies J Am Acad Dermatol 71 2014 116 132
4. J Ring, A Alomar, T Bieber et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II J Eur Acad Dermatol Venereol 26 2012 1176 1193
5. R Sidbury, DM Davis, DE Cohen et al. Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents J Am Acad Dermatol 71 2014 327 349
6. I Katayama, Y Kohno, K Akiyama et al. Japanese guidelines for atopic dermatitis 2014 Allergol Int 63 2014 377 398
7. E Roekevisch, PI Spuls, D Kuester, J Limpens, J Schmitt Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review J Allergy Clin Immunol 133 2014 429 438
8. T Muto, SD Hsieh, Y Sakurai et al. Prevalence of atopic dermatitis in Japanese adults Br J Dermatol 148 2003 117 121
9. JA Odhiambo, HC Williams, TO Clayton, CF Robertson, MI Asher the ISAAC Phase Three Study Group Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three J Allergy Clin Immunol 124 2009 1251 1258
10. JI Silverberg, JM Hanifin Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study J Allergy Clin Immunol 132 2013 1132 1138
11. SP McKenna, LC Doward Quality of life of children with atopic dermatitis and their families Curr Opin Allergy Clin Immunol 8 2008 228 231
12. MI Asher, S Montefort, B Björkstén et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys Lancet 368 2006 733 743
13. YS Punekar, A Sheikh Establishing the incidence and prevalence of clinician-diagnosed allergic conditions in children and adolescents using routinely collected data from general practices Clin Exp Allergy 39 2009 1209 1216
14. RK Chandra, D Lin, B Tan et al. Chronic rhinosinusitis in the setting of other chronic inflammatory diseases Am J Otolaryngol 32 2011 388 391
15. P Yaghmaie, CW Koudelka, EL Simpson Mental health comorbidity in patients with atopic dermatitis J Allergy Clin Immunol 131 2013 428 433
16. EL Simpson Comorbidity in atopic dermatitis Curr Dermatol Rep 1 2012 29 38
17. S Kaesler, T Volz, Y Skabytska et al. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10 J Allergy Clin Immunol 134 2014 92 99
18. JD Hamilton, M Suárez-Fariñas, N Dhingra et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis J Allergy Clin Immunol 134 2014 1293 1300
19. M Suárez-Fariñas, N Dhingra, J Gittler et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis J Allergy Clin Immunol 132 2013 361 370
20. LA Beck, D Thaçi, JD Hamilton et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis N Engl J Med 371 2014 130 139
21. S Wenzel, L Ford, D Pearlman et al. Dupilumab in persistent asthma with elevated eosinophil levels N Engl J Med 368 2013 2455 2466
22. C Bachert, L Mannent, RM Naclerio et al. Dupilumab in chronic sinusitis with nasal polyposis, with and without asthma Allergy 70 suppl 1 2015 107 (abstr 1516).
23. YA Leshem, T Hajar, JM Hanifin, EL Simpson What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study Br J Dermatol 172 2015 1353 1357
24. NQ Phan, C Blome, F Fritz et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus Acta Derm Venereol 92 2012 502 507
25. JM Hanifin, M Thurston, M Omoto, R Cherill, SJ Tofte, M Graeber The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group Exp Dermatol 10 2001 11 18
26. European Task Force on Atopic Dermatitis Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis Dermatology 186 1993 23 31
27. AY Finlay, GK Khan Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
28. J Schmitt, PI Spuls, KS Thomas et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials J Allergy Clin Immunol 134 2014 800 807
29. LF Eichenfield, BH Miller on behalf of a Cutivate Lotion Study Group Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age J Am Acad Dermatol 54 2006 715 717
30. C Bangert, BE Strober, M Cork et al. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial Dermatology 222 2011 36 48
31. D Chrostowska-Plak, A Reich, JC Szepietowski Relationship between itch and psychological status of patients with atopic dermatitis J Eur Acad Dermatol Venereol 27 2013 e239 e242
32. J Sánchez-Pérez, E Daudén-Tello, AM Mora, NL Surinyac Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study Actas Dermosifiliogr 104 2013 44 52